Clinical Review

Incorporating medication abortion into your ObGyn practice: Why and how

Author and Disclosure Information

Step-by-step guidance for how to provide safe and effective medication
abortion services for your patients


 

References

The Supreme Court’s Dobbs decision on June 24, 2022, which nullified the federal protections of Roe v Wade, resulted in the swift and devastating dissolution of access to abortion care for hundreds of thousands of patients in the United States.1 Within days of the decision, 11 states in the South and Midwest implemented complete or 6-week abortion bans that, in part, led to the closure of over half the abortion clinics in these states.2 Abortion bans, severe restrictions, and clinic closures affect all patients and magnify existing health care inequities.

Medication abortion is becoming increasingly popular; as of 2020, approximately 50% of US abortions were performed using this method.3 Through a combination of mifepristone and misoprostol, medication abortion induces the physiologic process and symptoms similar to those of a miscarriage. Notably, this regimen is also the most effective medical management method for a missed abortion in the first trimester, and therefore, should already be incorporated into any general ObGyn practice.4

Although a recent study found that 97% of ObGyn physicians report encountering patients who seek an abortion, only 15% to 25% of them reported providing abortion services.5,6 Given our expertise, ObGyns are well-positioned to incorporate medication abortion into our practices. For those ObGyn providers who practice in states without extreme abortion bans, this article provides guidance on how to incorporate medication abortion into your practice (FIGURE). Several states now have early gestational limits on abortion, and the abortion-dedicated clinics that remain open are over capacity. Therefore, by incorporating medication abortion into your practice you can contribute to timely abortion access for your patients.

Medication abortion: The process

Determine your ability and patient’s eligibility

Abortion-specific laws for your state have now become the first determinant of your ability to provide medication abortion to your patients. The Guttmacher Institute is one reliable source of specific state laws that your practice can reference and is updated regularly.7

From a practice perspective, most ObGyn physicians already have the technical capabilities in place to provide medication abortion. First, you must be able to accurately determine the patient’s gestational age by their last menstrual period, which is often confirmed through ultrasonography.

Medication abortion is safe and routinely used in many practices up to 77 days, or 11 weeks, of gestation. Authors of a recent retrospective cohort study found that medication abortion also may be initiated for a pregnancy of unknown location in patients who are asymptomatic and determined to have low risk for an ectopic pregnancy. In this study, initiation of medication abortion on the day of presentation, with concurrent evaluation for ectopic pregnancy, was associated with a shorter time to a completed abortion, but a lower rate of successful medication abortion when compared with patients who delayed the initiation of medication abortion until a clear intrauterine pregnancy was diagnosed.8

Few medical contraindications exist for patients who seek a medication abortion. These contraindications include allergy to or medication interaction with mifepristone or misoprostol, chronic adrenal failure or long-term corticosteroid therapy, acute porphyria, anemia or the use of anticoagulation therapy, or current intrauterine device (IUD) use.

Continue to: Gather consents and administer treatment...

Pages

Recommended Reading

Pursue multimodal pain management in patients taking opioids
MDedge ObGyn
Some women use prescription opioids during pregnancy
MDedge ObGyn
HHS will drop buprenorphine waiver rule for most physicians
MDedge ObGyn
Opioid prescribing laws having an impact
MDedge ObGyn
Opioid exposure in early pregnancy linked to congenital anomalies
MDedge ObGyn
Study questions reliability of maternal drug testing
MDedge ObGyn
ADHD link to prenatal opioid exposure shifts with other substances
MDedge ObGyn
Postpartum HCV treatment rare in infected mothers with opioid use disorder
MDedge ObGyn
Study: No more autopilot opioids after cesarean delivery
MDedge ObGyn
Buprenorphine linked with lower risk for neonatal harms than methadone
MDedge ObGyn